Siam Bioscience controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile2 entries
2021
Lèse-majesté proceedings linked to vaccine criticism
Thanathorn Juangroongruangkit was charged under Thailand's lèse-majesté law after criticizing the government's vaccine policy and its reliance on AstraZeneca production through Siam Bioscience. Additional charges were reported later in 2021. The proceedings concerned speech about government policy and the monarchy-linked company rather than a proven corporate offense.
2020
Public-funding and vaccine-capacity controversy
A 600 million baht government allocation to support Siam Bioscience's AstraZeneca vaccine-production capacity drew criticism from Thanathorn Juangroongruangkit over transparency and the provision of public funds to a for-profit company. The cited material reports political controversy but does not establish a finding of financial wrongdoing by the company.